Payment overview · 2025
General Payments
$442.02
24 reported records · 10 companies
Healthcare provider profile · identity verified
Marshall Scott Tynes, DO
Allopathic & Osteopathic Physicians|Family Medicine · MERIDIAN, MS · NPI 1063509719
Verified facts
What the public records show
CMS Open Payments records show Marshall Scott Tynes, DO received $442.02 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.40 | 21.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.14 | 19.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.68 | 17.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.31 | 11.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.99 | 10.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.32 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.23 | 3.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.80 | 3.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.67 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.48 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $442.02 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.68 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.66 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.09 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.09 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.09 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.75 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| VANTA ADAPTIVESTIM Normalized: vanta adaptivestim |
Device | Medtronic, Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 544 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 541 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 445 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 101 |
| Losartan Potassium | Losartan Potassium | 350 | 80 |
| Valsartan | Valsartan | 338 | 76 |
| Potassium Chloride | Potassium Chloride | 336 | 89 |
| Gabapentin | Gabapentin | 329 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 73 |
| Montelukast Sodium | Montelukast Sodium | 277 | 79 |
| Omeprazole | Omeprazole | 268 | 81 |
| Metformin Hcl | Metformin Hcl | 218 | 62 |
| Meloxicam | Meloxicam | 207 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 188 | 39 |
| Lisinopril | Lisinopril | 185 | 50 |
| Sertraline Hcl | Sertraline Hcl | 176 | 42 |
| Glimepiride | Glimepiride | 165 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 41 |
| Alendronate Sodium | Alendronate Sodium | 137 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 62 |
| Ozempic | Semaglutide | 114 | 19 |
| Simvastatin | Simvastatin | 114 | 31 |
| Farxiga | Dapagliflozin Propanediol | 111 | 25 |
| Buspirone Hcl | Buspirone Hcl | 106 | 24 |
| Allopurinol | Allopurinol | 105 | 27 |
| Memantine Hcl | Memantine Hcl | 103 | 22 |
| Metformin Hcl Er | Metformin Hcl | 100 | 24 |
| Famotidine | Famotidine | 96 | 24 |
| Furosemide | Furosemide | 96 | 29 |
| Carvedilol | Carvedilol | 95 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 19 |
| Alprazolam | Alprazolam | 92 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 90 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 19 |
| Methocarbamol | Methocarbamol | 81 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 13 |
| Trazodone Hcl | Trazodone Hcl | 68 | 14 |
| Repaglinide | Repaglinide | 67 | 17 |
| Synthroid | Levothyroxine Sodium | 65 | 17 |
| Glipizide | Glipizide | 64 | 18 |
| Spironolactone | Spironolactone | 63 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 15 |
| Donepezil Hcl | Donepezil Hcl | 59 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 52 |
| Irbesartan | Irbesartan | 59 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 14 |
| Naproxen | Naproxen | 53 | 13 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Eliquis | Apixaban | 51 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 14 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 15 |
| Linzess | Linaclotide | 44 | 16 |
| Azithromycin | Azithromycin | 41 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 13 |
| Lovastatin | Lovastatin | 33 | 11 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 20 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | 14 |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 17 |
| Finasteride | Finasteride | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | 13 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $442.02 · 24 records | PFIZER INC. | ABRYSVO, AIRSUPRA, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, PREVNAR 20, QULIPTA, REPATHA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VANTA ADAPTIVESTIM, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error